THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs

Author:

Boucheteil Marion1,Leobon Sophie1,Baffert Kim-Arthur1,Darbas Tiffany1,Peyramaure Clémentine1,brun-Ly Valérie Le1,Pestre Julia1,Venat Laurence1,Thuillier Frédéric1,HUET Soline1,Jost Jeremy1,Touati Mohamed1,DELUCHE Elise1

Affiliation:

1. Limoges University Hospital Center

Abstract

Abstract

Purpose: Recent developments in oral chemotherapy and targeted therapies have radically changed the way in which cancer patients are managed. Ambulatory care is now common, associated with the development of organizations that foster, secure home treatments, and reinforce the city hospital link. Methods: THERANOVA-LIM (NCT04931329), a prospective, interventional study, assessed the satisfaction of healthcare professionals and patients who benefited from improved access to information on appropriate drug use imparted by a drug vigilance card or a prescription with a QR code. Results: Initially, an e-questionnaire was used to explore the practices and expectations of retail pharmacists; only 40% stated that they felt comfortable when managing patients on oral therapy. A total of 128 patients were included in the study, 55 in a “medication vigilance card” group and 73 in a “prescription with QR code” group. Patients were satisfied with the new systems and with the simplicity afforded by both the card and the prescription (p = 0.8). Similarly, 93.2% of professionals were satisfied with the new system. However, they felt that the prescription with a QR code was of greater assistance than the drug vigilance card (p = 0.02). There was no significant between-group difference in compliance (p = 0.3595) Conclusion: The two systems improved the management of patients on oral chemotherapy; the QR-coded prescription was optimal. The fact that both patients and healthcare professionals were satisfied encourages us to extend the innovations and evaluate them further. Trial Registration Number and the date of registration: ClinicalTrials.gov, NCT04931329. 2021-05-10

Publisher

Springer Science and Business Media LLC

Reference42 articles.

1. Oral cancer treatment: developments in chemotherapy and beyond;O’Neill VJ;Br J Cancer,2002

2. National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study;Bosco-Lévy P;Pharmacoepidemiol Drug Saf,2017

3. National trends in the use of oral chemotherapy over 13 years;Moreira A;Front Pharmacol,2022

4. Chiffres clés de la chimiothérapie - Chimiothérapie. https://www.e-cancer.fr/Professionnels-de-sante/Les-traitements/Chimiotherapie/Chiffres-cles-de-la-chimiotherapie. Accessed 9 Sep 2023

5. Plan Cancer 2014–2019 - Ref: PLANKPNRT14. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Plan-Cancer-2014-2019. Accessed 9 Sep 2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3